What is argenx?
argenx is a immunology biotechnology company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Immunology biotechnology
- Headquarters
- Amsterdam, Netherlands
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq/Euronext: ARGX
What is argenx?
argenx is a immunology biotechnology company headquartered in Amsterdam, Netherlands. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
argenx is a immunology biotechnology company headquartered in Amsterdam, Netherlands. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, argenx should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does argenx offer?
argenx's profile centers on VYVGART, Antibody medicines, Autoimmune diseases, Clinical pipeline.
- VYVGART· Immunology biotechnology
- Antibody medicines· Immunology biotechnology
- Autoimmune diseases· Immunology biotechnology
- Clinical pipeline· Immunology biotechnology
- Immunology platform· Immunology biotechnology
- Commercial biotech· Immunology biotechnology
How does argenx make money?
argenx makes money through commercial activity tied to immunology biotechnology.
argenx monetizes through the model common to immunology biotechnology: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads argenx?
argenx's named executives should be verified on the official leadership or investor-relations page before outreach.
- argenx executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- argenx finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- argenx operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact argenx's leadership?
argenx should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.argenx.comHow is argenx funded?
argenx's current status is Public company; Nasdaq/Euronext: ARGX.
argenx's capital profile is best understood through its current public-company status: Public company; Nasdaq/Euronext: ARGX. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did argenx get here?
argenx's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- Foundingargenx is foundedThe company begins building in immunology biotechnology.
- Scale-upCommercial footprint expandsargenx broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq/Euronext: ARGXPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are argenx's competitors?
argenx competes with larger incumbents and focused specialists in immunology biotechnology.
argenx — frequently asked questions
